Ascletis Pharma Announces Breakthrough with Oral Small Molecule Amylin Receptor Agonist ASC39

Ascletis Pharma Inc. (Stock Code: 1672) has released a voluntary announcement detailing significant progress in its obesity drug pipeline, specifically concerning ASC39, a novel oral small molecule amylin receptor agonist. This development could have major implications for shareholders and potential investors, given the potential for ASC39 to become a first-in-class oral therapy for obesity, and the expected IND submission to the US FDA in Q3 2026.

Key Highlights and Potential Price Sensitive Information

• ASC39 Demonstrates Comparable Efficacy and Selectivity to Eloralintide:
  – In head-to-head preclinical assays, ASC39 showed similar selectivity and potency to eloralintide, Eli Lilly’s peptide-based amylin receptor agonist.
  – EC₅₀ for human amylin 1 receptor (hAMY1R): 21.4 pM (ASC39) vs. 21.2 pM (eloralintide)
  – EC₅₀ for human calcitonin receptor (hCTR): 846.1 pM (ASC39) vs. 1,350.8 pM (eloralintide)
  – Both compounds were 40-fold (ASC39) and 64-fold (eloralintide) more selective for hAMY1R over hCTR.
  – These results confirm ASC39’s high selectivity and comparable efficacy profile to eloralintide.
• Positive Preclinical Efficacy in Obese Rat Models:
  – In diet-induced obese (DIO) rats, oral ASC39 produced significant, placebo-adjusted weight loss of 6.6% over six days.
  – Eloralintide delivered via subcutaneous injection produced a 5.6% weight loss.
  – The oral dosing (5 mg/kg, once daily) of ASC39 achieved statistically significant body weight reduction, potentially offering a more convenient therapy versus injectable peptides.
• Favorable Pharmacokinetics Supporting Once-Daily Oral Dosing:
  – ASC39 demonstrated favorable pharmacokinetic profiles in both rats and non-human primates, supporting its use as a once-daily oral medication in humans.
• FDA IND Submission Scheduled for Q3 2026:
  – Ascletis plans to submit an Investigational New Drug (IND) application to the US FDA for ASC39 oral tablets for the treatment of obesity in the third quarter of 2026. This milestone may be a significant price-sensitive event for the company.
• Potential Commercial Advantages:
  – ASC39 could offer efficacy and safety similar to Eli Lilly’s eloralintide but with the convenience and scalability of a once-daily oral small molecule, potentially disrupting the current injectable market and expanding patient access.
• Pipeline Expansion:
  – ASC39 is being developed both as monotherapy and in combination with ASC30 (Ascletis’ Phase III ready oral GLP-1), targeting metabolic diseases including obesity.
  – This oral small molecule amylin candidate complements Ascletis’ existing amylin peptide portfolio (ASC36 and ASC35).
• AI-Driven Drug Discovery:
  – ASC39 was discovered using Ascletis’ proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) technology, underscoring the company’s innovation capabilities.
• Management and Commitment:
  – Dr. Jinzi Jason Wu, Founder, Chairman and CEO, emphasized Ascletis’ commitment to obesity treatments and highlighted ASC39 as the first oral small molecule eloralintide-like amylin receptor agonist entering clinical development.
• Cautionary Statement:
  – The company notes that there can be no guarantee ASC39 will be successfully developed, manufactured, or commercialized.

Implications for Investors and Shareholders

• This announcement presents a potentially significant share price catalyst due to the clinical advancement of a novel oral obesity drug with comparable efficacy to a leading injectable competitor.
• The expected IND submission to the FDA in Q3 2026 could drive investor interest and valuation as the program advances towards human clinical trials.
• The oral nature of ASC39, coupled with its demonstrated efficacy, could enable rapid market uptake and broader patient adoption compared to injectable solutions.
• Ascletis’ pipeline diversification and AI-driven drug discovery platform highlight sustained innovation and growth potential.

Table: Preclinical Efficacy in Obese Rats

Management and Board Composition

• Chairman: Dr. Jinzi Jason Wu
• Executive Directors: Dr. Jinzi Jason Wu, Mrs. Judy Hejingdao Wu
• Independent Non-Executive Directors: Dr. Yizhen Wei, Mr. Jiong Gu, Ms. Lin Hua

Summary

Ascletis Pharma’s advancement of ASC39 as a first-in-class oral amylin receptor agonist for obesity treatment represents a notable potential value driver, with preclinical data supporting efficacy and selectivity comparable to a leading injectable competitor. The planned IND filing with the FDA in Q3 2026 and the innovative AI-driven drug discovery approach highlight the company’s progress and potential for future growth. Investors should monitor further updates, as clinical milestones could significantly impact share value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The development and commercialization of ASC39 are subject to regulatory, technical, and commercial risks. Investors should perform their own due diligence and consult professional advisors before making investment decisions.

View ASCLETIS-B Historical chart here